<DOC>
	<DOC>NCT00396240</DOC>
	<brief_summary>24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.</brief_summary>
	<brief_title>ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Primary hypercholesterolaemia: Statin na√Øve subjects (LDLC level &gt; 3.5 mmol/L) or subjects on an ineffective "start dose" of a lipidlowering therapy (LDLC level &gt; 3.1 mmol/L). CV risk &gt; 20%, history of CHD or other established atherosclerotic disease History of severe adverse events with another HMGCoA reductase inhibitor Secondary hypercholesterolaemia; Unstable cardiovascular disease; Uncontrolled diabetes, active liver disease; Severe hepatic or renal impairment; Treatment with cyclosporin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>LDL-C</keyword>
	<keyword>triglyceride</keyword>
	<keyword>plasma lipids</keyword>
	<keyword>compliance</keyword>
</DOC>